MoonLake's Phase 3 psoriatic arthritis trial met all Week 16 endpoints; Q2 expenses fell
MoonLake Immunotherapeutics reported positive topline Week 16 results from its Phase 3 IZAR-1 trial of sonelokimab in biologic-naive psoriatic arthritis patients, with 42.1% of patients on the 60 mg induction dose achieving an ACR50 response. The company also reported second quarter 2026 results, with cash of $537.0 million and a stated cash runway to mid-2028, and the filing notes that comparisons against placebo remain blinded until the Phase 3 program is complete.
Key points
- IZAR-1 met all clinical endpoints at Week 16 for the 60 mg sonelokimab arm; 42.1% achieved ACR50 and 66.5% achieved ACR20.
- Research and development expenses were $50.2 million in the quarter ended June 30, 2026, down from $54.5 million in the prior quarter; general and administrative expenses were $11.4 million, down from $15.5 million.
- Cash, cash equivalents and short-term marketable debt securities were $537.0 million as of June 30, 2026; up to $400 million more is available through a Hercules Capital debt facility.
- The IZAR-1 trial remains blinded and continues to Week 52, with the full readout expected in H1 2027.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 10, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.